COMMUNIQUÉS West-GlobeNewswire

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02/02/2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced [...]
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
02/02/2024
FOSTER CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02/02/2024
TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), known as "NurExone," is pleased to announce the initiation of the Orphan Drug Designation process with [...]
Mydecine Innovations Group Announces Director Resignation
02/02/2024
VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to [...]
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
02/02/2024
NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the closing [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the Compensation Committee of the [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/02/2024
BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
The International Myeloma Foundation (IMF) Welcomes Dr. S. Vincent Rajkumar as Chairperson of the Board
02/02/2024
STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new [...]
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
02/02/2024
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of [...]
TeamHealth launches new value-based care initiative, TeamACO
02/02/2024
TeamACO is one of the largest accountable care organizations focusing on care delivery for post-acute care patients KNOXVILLE, Tenn., Feb. 02, 2024 (GLOBE NEWSWIRE) -- TeamHealth, the leading physician practice in the [...]
Cooperative of American Physicians’ Mutual Protection Trust Earns 17th Consecutive A.M. Best A+ (Superior) Rating
02/02/2024
LOS ANGELES, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The Cooperative of American Physicians, Inc. (CAP) announced that A.M. Best has reaffirmed its A+ (Superior) rating for the Mutual Protection Trust (MPT), California's [...]
Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
02/02/2024
PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Women’s Health Advocates Call on Province of New Brunswick and Premier Higgs to act urgently following the closure announcement of Clinic 554
02/02/2024
OTTAWA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Following the announcement of the closure of Clinic 554 in Fredericton, the Society of Obstetricians and Gynaecologists of Canada (SOGC) calls on the Province of New Brunswick [...]
Un défenseur de la santé des femmes demande à la province du Nouveau-Brunswick et au premier ministre Higgs d'agir de façon urgente suite à l'annonce de la fermeture de la clinique 554
02/02/2024
OTTAWA, 02 févr. 2024 (GLOBE NEWSWIRE) -- Suite à l'annonce de la fermeture de la Clinique 554 à Fredericton, la Société des obstétriciens et gynécologues du Canada (SOGC) demande à la province du Nouveau-Brunswick et [...]
BioSenic raises €500,000 in private placement of new shares with established new investors
02/02/2024
PRESS RELEASE – REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER [...]
BioSenic lève 500 000 euros dans le cadre d'un placement privé d'actions nouvelles auprès de nouveaux investisseurs établis
02/02/2024
COMMUNIQUE DE PRESSE – INFORMATION REGULEE NE PAS PUBLIER, DISTRIBUER OU DIFFUSER, EN TOUT OU EN PARTIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD OU DANS TOUTE [...]
Cingulate Announces Pricing of $7.5 Million Public Offering
02/02/2024
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR [...]
Evaxion Biotech fixe le prix de son offre publique à 15 millions de dollars
02/02/2024
COPENHAGUE, Danemark, 02 févr. 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique spécialisée dans le [...]

Pages